HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
1-cyclopropylisoguanosine
an adenosine A1 agonist
Also Known As:
BN 063; BN-063; Adenosine, 1-cyclopropyl-1,2-dihydro-2-oxo-
Networked:
3
relevant articles (
2
outcomes,
1
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
Fused-Ring Heterocyclic Compounds
2-Ring Heterocyclic Compounds
Purines: 651
Purine Nucleosides: 360
Guanosine: 1156
1-cyclopropylisoguanosine: 3
Nucleic Acids, Nucleotides, and Nucleosides: 1
Nucleosides: 6847
Purine Nucleosides: 360
Guanosine: 1156
1-cyclopropylisoguanosine: 3
Ribonucleosides: 49
Guanosine: 1156
1-cyclopropylisoguanosine: 3
Related Diseases
1.
Infarction (Infarctions)
06/12/1995 - "
A significant reduction in infarct size, as a percentage of the area at risk, was noted with all three BN-063 treatment groups (control: 63.5 +/- 4.0%, I0.5-R0.5: 39.6 +/- 3.7%, R-0.5: 37.5 +/- 3.5%, R-1.0: 38.1 +/- 5.2%).
"
06/12/1995 - "
The results of this study demonstrate that BN-063, through activation of adenosine A1 receptors, exerts antiarrhythmic and anti-infarct effects during myocardial ischemia-reperfusion.
"
2.
Ventricular Tachycardia
08/01/1994 - "
Pretreatment with BN-063 (0.25, 0.5 and 1.0 mg kg-1) 10 min prior to occlusion significantly delayed the onset of ventricular arrhythmias, reduced the total number of ventricular premature contraction (VPC) and ventricular tachycardia (VT), decreased the incidence of VT and ventricular fibrillation (VF) and mortality during the first 30 min following left coronary artery ligation.
"
3.
Myocardial Reperfusion Injury
06/12/1995 - "
To assess the efficacy of the newly synthesized selective adenosine A1 receptor agonist, BN-063 (1-cyclopropylisoguanosine), against myocardial reperfusion injury, 31 rats underwent 45 min of left coronary artery occlusion and 1 h of reperfusion.
"
06/12/1995 - "
BN-063, a newly synthesized adenosine A1 receptor agonist, attenuates myocardial reperfusion injury in rats.
"
4.
Ventricular Fibrillation
08/01/1994 - "
Pretreatment with BN-063 (0.25, 0.5 and 1.0 mg kg-1) 10 min prior to occlusion significantly delayed the onset of ventricular arrhythmias, reduced the total number of ventricular premature contraction (VPC) and ventricular tachycardia (VT), decreased the incidence of VT and ventricular fibrillation (VF) and mortality during the first 30 min following left coronary artery ligation.
"
5.
Myocardial Ischemia (Ischemic Heart Diseases)
06/12/1995 - "
The results of this study demonstrate that BN-063, through activation of adenosine A1 receptors, exerts antiarrhythmic and anti-infarct effects during myocardial ischemia-reperfusion.
"
Related Drugs and Biologics
1.
Adenosine A1 Receptor
Related Therapies and Procedures
1.
Ligation